CY1109400T1 - Αναστολεις μεταλλοπρωτεϊνασης μητρας - Google Patents

Αναστολεις μεταλλοπρωτεϊνασης μητρας

Info

Publication number
CY1109400T1
CY1109400T1 CY20091100090T CY091100090T CY1109400T1 CY 1109400 T1 CY1109400 T1 CY 1109400T1 CY 20091100090 T CY20091100090 T CY 20091100090T CY 091100090 T CY091100090 T CY 091100090T CY 1109400 T1 CY1109400 T1 CY 1109400T1
Authority
CY
Cyprus
Prior art keywords
alkyl
alkylaryl
cor
optionally substituted
bond
Prior art date
Application number
CY20091100090T
Other languages
Greek (el)
English (en)
Inventor
Simon Gaines
Ian Peter Holmes
Stephen Lewis Martin
Stephen Paul Watson
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of CY1109400T1 publication Critical patent/CY1109400T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Soft Magnetic Materials (AREA)
  • Indole Compounds (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CY20091100090T 2003-09-13 2009-01-27 Αναστολεις μεταλλοπρωτεϊνασης μητρας CY1109400T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0321538.1A GB0321538D0 (en) 2003-09-13 2003-09-13 Therapeutically useful compounds
EP04765231A EP1663970B1 (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
CY1109400T1 true CY1109400T1 (el) 2014-07-02

Family

ID=29227079

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100090T CY1109400T1 (el) 2003-09-13 2009-01-27 Αναστολεις μεταλλοπρωτεϊνασης μητρας

Country Status (28)

Country Link
US (3) US7601729B2 (enExample)
EP (3) EP1663970B1 (enExample)
JP (3) JP2007505081A (enExample)
KR (3) KR20130079628A (enExample)
CN (1) CN1849306B (enExample)
AT (2) ATE502922T1 (enExample)
AU (1) AU2004272280C1 (enExample)
BR (1) BRPI0413791A (enExample)
CA (1) CA2538315C (enExample)
CY (1) CY1109400T1 (enExample)
DE (2) DE602004031991D1 (enExample)
DK (1) DK1663970T3 (enExample)
ES (2) ES2362954T3 (enExample)
GB (1) GB0321538D0 (enExample)
HR (1) HRP20080668T3 (enExample)
IL (1) IL173305A (enExample)
IS (2) IS2622B (enExample)
MA (1) MA28039A1 (enExample)
MX (1) MXPA06002458A (enExample)
NO (1) NO20060540L (enExample)
NZ (2) NZ573479A (enExample)
PL (1) PL1663970T3 (enExample)
PT (1) PT1663970E (enExample)
RU (2) RU2370488C2 (enExample)
SG (1) SG145685A1 (enExample)
SI (1) SI1663970T1 (enExample)
WO (1) WO2005026120A1 (enExample)
ZA (1) ZA200602070B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
DK1856063T3 (da) * 2005-02-22 2012-03-26 Ranbaxy Lab Ltd 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme
AU2013200728B2 (en) * 2006-08-22 2014-12-18 Sun Pharmaceutical Industries Limited Matrix metalloproteinase inhibitors
BRPI0715231A2 (pt) * 2006-08-22 2013-06-25 Ranbaxy Lab Ltd compostos, composiÇÕes farmacÊuticas e seus usos, auxiliar quiral e seu uso e processos para preparar um composto
EP2520561B1 (en) 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
FR2949463B1 (fr) * 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp
SG187654A1 (en) 2010-07-30 2013-03-28 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
JP2013540754A (ja) 2010-09-24 2013-11-07 ランバクシー ラボラトリーズ リミテッド マトリックスメタロプロテイナーゼ阻害剤
US20160045463A1 (en) 2012-11-28 2016-02-18 Universidad De Salamanca Use of metalloprotease inhibitors in the treatment of polycystic liver diseases
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
JP7143334B2 (ja) * 2017-06-13 2022-09-28 エシコン エルエルシー 治癒を制御させる手術用ステープラ

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1995029901A1 (en) * 1994-04-28 1995-11-09 Uniroyal Chemical Company, Inc. Fungicidal azole derivatives
HUP9900143A3 (en) * 1995-12-06 2000-04-28 Astra Pharmaceuticals Ltd King Pharmaceutically useful 3-pyridil-compounds
NZ332334A (en) 1996-04-19 2000-06-23 Akzo Nobel Nv Substituted benzylamines and their use for the treatment of depression and other neurologically related disorders
HRP970246B1 (en) * 1996-05-15 2002-04-30 Bayer Ag Substituted oxobutric acids as matrix metalloprotease inhibitors
US5789605A (en) 1996-12-03 1998-08-04 Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof
US20050065353A1 (en) 1996-12-03 2005-03-24 Smith Amos B. Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
US6870058B2 (en) 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US6242616B1 (en) 1996-12-03 2001-06-05 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US6096904A (en) 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US5804581A (en) * 1997-05-15 1998-09-08 Bayer Corporation Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US6608052B2 (en) * 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
CA2490819A1 (en) * 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2004012663A2 (en) 2002-08-01 2004-02-12 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
DE60330997D1 (de) * 2002-11-19 2010-03-04 Galderma Res & Dev Biaromatische verbindungen die ppar-gamma rezeptoren aktivieren und deren anwendungen in kosmetischen oder pharmazeutischen zusammensetzungen
GB0312654D0 (en) 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
GB0314488D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
GB0319069D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
DK1856063T3 (da) 2005-02-22 2012-03-26 Ranbaxy Lab Ltd 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme
BRPI0715231A2 (pt) 2006-08-22 2013-06-25 Ranbaxy Lab Ltd compostos, composiÇÕes farmacÊuticas e seus usos, auxiliar quiral e seu uso e processos para preparar um composto

Also Published As

Publication number Publication date
PT1663970E (pt) 2009-01-09
ATE502922T1 (de) 2011-04-15
AU2004272280B2 (en) 2011-04-21
HRP20080668T3 (hr) 2009-02-28
IL173305A (en) 2011-01-31
DE602004017622D1 (de) 2008-12-18
US20100029699A1 (en) 2010-02-04
AU2004272280A1 (en) 2005-03-24
CA2538315C (en) 2014-04-08
CA2538315A1 (en) 2005-03-24
IS8843A (is) 2009-08-19
US7601729B2 (en) 2009-10-13
ES2362954T3 (es) 2011-07-15
MXPA06002458A (es) 2006-06-20
DK1663970T3 (da) 2009-01-12
JP2011231118A (ja) 2011-11-17
IL173305A0 (en) 2006-06-11
CN1849306B (zh) 2014-01-29
MA28039A1 (fr) 2006-07-03
GB0321538D0 (en) 2003-10-15
ZA200602070B (en) 2007-05-30
RU2370488C2 (ru) 2009-10-20
JP2012107031A (ja) 2012-06-07
SG145685A1 (en) 2008-09-29
ATE413384T1 (de) 2008-11-15
NZ545211A (en) 2009-01-31
BRPI0413791A (pt) 2006-11-07
EP2042488A1 (en) 2009-04-01
US8263602B2 (en) 2012-09-11
KR20130079628A (ko) 2013-07-10
AU2004272280C1 (en) 2011-10-27
US8343986B2 (en) 2013-01-01
SI1663970T1 (sl) 2009-04-30
KR20120007566A (ko) 2012-01-20
RU2006106850A (ru) 2007-10-20
KR20060120648A (ko) 2006-11-27
EP1663970B1 (en) 2008-11-05
US20090082377A1 (en) 2009-03-26
NZ573479A (en) 2010-09-30
IS2622B (is) 2010-05-15
PL1663970T3 (pl) 2009-04-30
ES2314436T3 (es) 2009-03-16
DE602004031991D1 (de) 2011-05-05
HK1092141A1 (en) 2007-02-02
US20060293353A1 (en) 2006-12-28
EP2042488B1 (en) 2011-03-23
JP2007505081A (ja) 2007-03-08
CN1849306A (zh) 2006-10-18
RU2008146479A (ru) 2010-06-20
NO20060540L (no) 2006-04-04
WO2005026120A1 (en) 2005-03-24
EP1663970A1 (en) 2006-06-07
EP2295408A1 (en) 2011-03-16
IS8268A (is) 2006-01-26

Similar Documents

Publication Publication Date Title
CY1109400T1 (el) Αναστολεις μεταλλοπρωτεϊνασης μητρας
ATE362910T1 (de) Matrix metalloprotease inhibitoren
NO20013254D0 (no) Nye difenylureaforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske samensetninger som inneholder dem
EA200000431A2 (ru) Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их
ATE92928T1 (de) Imidazo(2,1-b)benzothiazole und ihre saeureadditionssalze, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen.
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
HUP0201475A2 (hu) Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
DK1010698T3 (da) Hidtil ukendte derivater af 1,2-dithiolan, fremgangsmåde til fremstiling deraf og farmaceutiske sammensætninger indeholdende dem
YU74201A (sh) Nova sinteza prstena piperazina
EA200000530A1 (ru) НОВЫЕ 19-НОРСТЕРОИДЫ, ЗАМЕЩЕННЫЕ В ПОЛОЖЕНИИ 11β, СПОСОБ И ПРОМЕЖУТОЧНЫЕ ПРОДУКТЫ ДЛЯ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
EA200001077A3 (ru) Новые соединения аминопирролина, способ их получения и содержащие их фармацевтические композиции
FR2795730B1 (fr) Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB1398687A (en) Substituted oxazolidinones and pharmaceutical uses thereof
DK0955310T3 (da) Hidtil ukendte (3,4,7,8,9,10)-hexahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-carboxylsyrederivater, fremgangsmåde til fremstilling af disse og anvendelse af disse til fremstilling af lægemidler
DK1188752T3 (da) Fremgangsmåde til fremstilling af substitueret alkylaminderivat
EA200200379A2 (ru) Новые соединения пиримидин-4-она, способ их получения и содержащие их фармацевтические композиции
ES2058182T3 (es) Analogos de mitomicina. un procedimiento para su preparacion y composiciones farmaceuticas.
GB1183442A (enExample)
EA200300302A1 (ru) Новые производные индолина, способ их получения и фармацевтические композиции, содержащие их